Melinta Therapeutics, LLC announced that it has acquired the U.S. rights to TOPROL-XL® (metoprolol succinate) and its Authorized Generic (AG) through an agreement between Melinta and New American Therapeutics Inc. TOPROL-XL®, approved by the FDA in 1992, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic (NYHA class II or III) heart failure of specific origins. Melinta has begun the integration process to bring TOPROL-XL® into the company's existing production, distribution and commercialization structure to ensure this important medication will continue to be made available without interruption.